Stallion India Fluorochemicals Q1 FY27 PAT Surges 79% YoY to ₹18.57 Crore
Stallion India Fluorochemicals reported a strong Q1 FY27 with PAT surging 79% YoY to ₹18.57 crore. Revenue grew 12.78% to ₹124.68 crore, and EBITDA increased 75.85% to ₹25.27 crore. High-purity helium processing at Khalapur facility is complete, commercial operations expected next quarter. Mambattu facility to start by Nov-Dec 2026.
The substantial increase in PAT and revenue, coupled with progress on key expansion projects like the helium processing and R-32 manufacturing facilities, are material positive developments for the company.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with positive operational updates and a confident management outlook for future growth.
Stallion India Fluorochemicals Limited (SIFL) has announced its unaudited financial results for the first quarter of FY27, reporting a significant year-on-year increase in profitability.
For Q1 FY26-27, SIFL's Profit After Tax (PAT) surged by 79.15% to ₹18.57 crore (₹1,856.58 lakhs), compared to ₹10.36 crore (₹1,036.32 lakhs) in the corresponding quarter of the previous fiscal year. Total Revenue for the quarter grew by 12.78% to ₹124.68 crore (₹12,467.57 lakhs), up from ₹110.55 crore (₹11,054.55 lakhs) in Q1 FY25-26. EBITDA saw a substantial increase of 75.85%, reaching ₹25.27 crore (₹2,526.79 lakhs) from ₹14.37 crore (₹1,436.94 lakhs) in the prior year period. Profit Before Tax (PBT) also rose by 78.83% to ₹24.79 crore (₹2,478.88 lakhs).
Operationally, the company completed preparations for high-purity helium processing at its Khalapur facility, which has an installed capacity of 1,200 MT per annum. Commercial operations for this facility are expected to commence in the upcoming quarter. The Mambattu, Andhra Pradesh facility is on track and anticipated to start operations between November and December 2026. Additionally, the development of the 10,000 MT per annum R-32 manufacturing facility at Bhilwara, Rajasthan, is progressing towards completion by the end of December 2026.
The management expressed confidence in achieving a 30-35% revenue CAGR over the next three years, with backward integration and higher-value specialty gases projected to improve EBITDA margins by approximately 3-4% in the medium term. The company is also exploring long-term Helium Recovery and Liquefaction solutions for space applications in collaboration with ISRO.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.